FDAnews

BEIJING MED-PHARM CORP. ANNOUNCES IT'S INTENT TO ACQUIRE MAJORITY INTEREST IN RONGHENG CORP

Beijing Med-Pharm Corporation (BJGP.PK) today announced that it has signed a non-binding letter of intent with Orient International Holding Shanghai Rongheng International Trading Co., Ltd., (" Orient International"), and Shanghai CAS Shenglongda Biotech (Group) Co., Ltd. ("Shanghai CAS") to purchase a majority interest of Shanghai Rongheng Pharmaceutical Company Limited ("Rongheng"). Orient International and Shanghai CAS currently own approximately 90% of the equity interests in Rongheng.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050906005412&newsLang=en)

(http://www.asahi.com/english/Herald-asahi/TKY200509010307.html)